Our work suggests that selective targeting of the two MMP-2 isoforms could represent a potential novel therapeutic approach for the prevention or treatment of diabetic nephropathy, in addition to the recognized approaches of stringent control of blood glucose and lipids. The gene discussed is MMP2; the disease is diabetic kidney disease.